Ultragenyx Stock Plunges After Phase 3 Failure in Angelman Syndrome GTX-102 failed Phase 3 in Angelman syndrome. Ultragenyx will review the program and reduce expenses. Credit: Ultragenyx Pharmaceutical Subscribe now Already have an account? Sign in.
